TY - JOUR
T1 - A cis-acting peptide signal in human immunodeficiency virus type I Rev which inhibits nuclear entry of small proteins
AU - Kubota, Satoshi
AU - Pomerantz, Roger J.
N1 - Funding Information:
The authors wish to thank Drs Bryan R Cullen for the antibody Rev1/20, Michael H Malim for pcREV mutants, Yoshifumi Adachi for anti-RexC antibody, and Masakazu Hatanaka for pKCR21x. We also wish to thank Ms Rita M Victor and Ms Brenda O Gordon for excellent secretarial assistance. This work was supported in part by US PHS grants A136552 and and A131836 to RJP.
PY - 1998/4/9
Y1 - 1998/4/9
N2 - A peptide signal, which may control nucleo-cytoplasmic protein trafficking, was newly identified in human immunodeficiency virus type I (HIV-1) Rev, a lentiviral post-transcriptional transactivator. The sequence, in the amino-terminal portion of HIV-1 Rev, maintains a Rev mutant with a dysfunctional nuclear/nucleolar targeting signal outside of the nucleus, although this Rev molecule itself is small enough to pass through the nuclear pores. Transition of this sequence to the N-terminus of human T-lymphocytic leukemia/lymphoma virus type I (HTLV-I) p21(x), which is usually located evenly distributed throughout the cell, resulted in capture of p21(x) in the cytoplasm. Mutational analysis clarified that a 14 residue peptide sequence was sufficient to display this inhibitory effect against nuclear entry. Furthermore, this HIV-I Rev sequence was capable of inhibiting nuclear entry of a fragment of a human ribosomal protein, when it was fused to the carboxy terminus. The identified nuclear entry inhibitory signal (NIS) contains a conserved hydrophilicity motif, which forms an amphipathic helix. Significantly, this motif and its helical structure were shown to be important for NIS function and the HIV-1 Rev function itself. Possible roles for NIS as a molecular anchor are proposed herein.
AB - A peptide signal, which may control nucleo-cytoplasmic protein trafficking, was newly identified in human immunodeficiency virus type I (HIV-1) Rev, a lentiviral post-transcriptional transactivator. The sequence, in the amino-terminal portion of HIV-1 Rev, maintains a Rev mutant with a dysfunctional nuclear/nucleolar targeting signal outside of the nucleus, although this Rev molecule itself is small enough to pass through the nuclear pores. Transition of this sequence to the N-terminus of human T-lymphocytic leukemia/lymphoma virus type I (HTLV-I) p21(x), which is usually located evenly distributed throughout the cell, resulted in capture of p21(x) in the cytoplasm. Mutational analysis clarified that a 14 residue peptide sequence was sufficient to display this inhibitory effect against nuclear entry. Furthermore, this HIV-I Rev sequence was capable of inhibiting nuclear entry of a fragment of a human ribosomal protein, when it was fused to the carboxy terminus. The identified nuclear entry inhibitory signal (NIS) contains a conserved hydrophilicity motif, which forms an amphipathic helix. Significantly, this motif and its helical structure were shown to be important for NIS function and the HIV-1 Rev function itself. Possible roles for NIS as a molecular anchor are proposed herein.
KW - Entry
KW - HIV-1
KW - Nucleus
KW - Rev
KW - Transport
UR - http://www.scopus.com/inward/record.url?scp=0032499220&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032499220&partnerID=8YFLogxK
U2 - 10.1038/sj.onc.1201738
DO - 10.1038/sj.onc.1201738
M3 - Article
C2 - 9583682
AN - SCOPUS:0032499220
SN - 0950-9232
VL - 16
SP - 1851
EP - 1861
JO - Oncogene
JF - Oncogene
IS - 14
ER -